Janus Henderson Group PLC Sarepta Therapeutics, Inc. Transaction History

Janus Henderson Group PLC

$187 Billion
Q3 2024

A detailed history of Janus Henderson Group PLC transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 4,358,511 shares of SRPT stock, worth $519 Million. This represents 0.29% of its overall portfolio holdings.

Number of Shares

4,358,511

Previous 3,815,368 14.24%

Holding current value

$519 Million

Previous $603 Million 9.7%

% of portfolio

0.29%

Previous 0.33%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$124.33 - $156.75 $67.5 Million - $85.1 Million	543,143 Added 14.24%	4,358,511 $544 Million
Q2 2024 Aug 14, 2024	SELL	$113.33 - $163.85 $122 Million - $176 Million	-1,076,049 Reduced 22.0%	3,815,368 $603 Million
Q1 2024 May 15, 2024	SELL	$93.7 - $141.53 $42.6 Million - $64.3 Million	-454,368 Reduced 8.5%	4,891,417 $633 Million
Q4 2023 Feb 14, 2024	SELL	$67.31 - $124.76 $29.4 Million - $54.5 Million	-436,664 Reduced 7.55%	5,345,785 $515 Million
Q3 2023 Nov 14, 2023	BUY	$102.5 - $123.59 $34.3 Million - $41.4 Million	334,782 Added 6.15%	5,782,449 $701 Million
Q2 2023 Aug 14, 2023	BUY	$106.4 - $157.19 $57.4 Million - $84.8 Million	539,463 Added 10.99%	5,447,667 $624 Million
Q1 2023 May 15, 2023	SELL	$117.53 - $155.99 $132 Million - $175 Million	-1,119,812 Reduced 18.58%	4,908,204 $676 Million
Q4 2022 Feb 14, 2023	SELL	$100.86 - $132.13 $45.4 Million - $59.5 Million	-449,973 Reduced 6.95%	6,028,016 $781 Million
Q3 2022 Nov 14, 2022	SELL	$75.71 - $119.24 $57.1 Million - $90 Million	-754,683 Reduced 10.43%	6,477,989 $716 Million
Q2 2022 Aug 15, 2022	SELL	$62.69 - $88.44 $14.2 Million - $20 Million	-225,910 Reduced 3.03%	7,232,672 $542 Million
Q1 2022 May 16, 2022	BUY	$63.15 - $90.42 $13.4 Million - $19.2 Million	212,720 Added 2.94%	7,458,582 $583 Million
Q4 2021 Feb 14, 2022	SELL	$77.28 - $99.42 $11.8 Million - $15.2 Million	-152,736 Reduced 2.06%	7,245,862 $652 Million
Q3 2021 Nov 16, 2021	BUY	$65.97 - $92.48 $33.2 Million - $46.6 Million	503,833 Added 7.31%	7,398,598 $684 Million
Q2 2021 Aug 16, 2021	BUY	$69.38 - $86.75 $50.2 Million - $62.7 Million	722,902 Added 11.71%	6,894,765 $536 Million
Q1 2021 May 17, 2021	BUY	$72.25 - $168.95 $166 Million - $388 Million	2,296,187 Added 59.25%	6,171,863 $460 Million
Q4 2020 Feb 16, 2021	SELL	$125.56 - $178.74 $9.4 Million - $13.4 Million	-74,876 Reduced 1.9%	3,875,676 $661 Million
Q3 2020 Nov 16, 2020	BUY	$127.12 - $172.34 $42.3 Million - $57.3 Million	332,723 Added 9.2%	3,950,552 $555 Million
Q2 2020 Aug 14, 2020	BUY	$93.0 - $171.7 $8.73 Million - $16.1 Million	93,846 Added 2.66%	3,617,829 $580 Million
Q1 2020 May 14, 2020	BUY	$82.38 - $131.64 $29.1 Million - $46.5 Million	353,301 Added 11.14%	3,523,983 $345 Million
Q4 2019 Feb 18, 2020	BUY	$76.53 - $135.58 $66.2 Million - $117 Million	865,342 Added 37.54%	3,170,682 $409 Million
Q3 2019 Nov 14, 2019	SELL	$72.81 - $156.91 $30.8 Million - $66.3 Million	-422,742 Reduced 15.5%	2,305,340 $174 Million
Q2 2019 Jul 31, 2019	BUY	$112.21 - $151.95 $6.96 Million - $9.43 Million	62,039 Added 2.33%	2,728,082 $415 Million
Q1 2019 Apr 30, 2019	BUY	$106.67 - $151.68 $88.2 Million - $125 Million	826,449 Added 44.93%	2,666,043 $318 Million
Q4 2018 Feb 06, 2019	BUY	$97.32 - $148.76 $139 Million - $213 Million	1,431,172 Added 350.42%	1,839,594 $201 Million
Q3 2018 Nov 09, 2018	BUY	$115.31 - $161.51 $46.8 Million - $65.6 Million	406,022 Added 16917.58%	408,422 $66 Million
Q2 2018 Aug 10, 2018	BUY	$71.74 - $153.69 $172,176 - $368,856	2,400 New	2,400 $317,000

Others Institutions Holding SRPT

# of Institutions

529

Shares Held

84.2M

Call Options Held

2.06M

Put Options Held

1.52M

View Full List

About Sarepta Therapeutics, Inc.

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $10.4B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

More about SRPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.

Account

Janus Henderson Group PLC Sarepta Therapeutics, Inc. Transaction History